Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases, Hypogammaglobulinemia, CIDP), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Intravenous Immunoglobulin Market Growth & Trends
The global intravenous immunoglobulin market size is expected to reach USD 21.1 billion by 2030, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 7.3% from 2022 to 2030. The increasing prevalence of immunodeficiency diseases, coupled with the adoption of intravenous immunoglobulin (IVIG) therapies, is expected to fuel market growth over the forecast period. In addition, increasing off-label use of immunoglobulin and investments in the healthcare sector are factors propelling the market growth. Moreover, increasing incidences of bleeding disorders and the growing geriatric population are the factors contributing to the industry growth.
The rising incorporation of subcutaneous immunoglobulin in the treatment of primary immunodeficiency diseases as well as in replacement therapy is anticipated to provide a growth platform to the market in the next seven years. Moreover, the key market players are focusing on breakthrough product introductions to expand their global distribution network. For instance, Octapharma U.S. got FDA clearance in July 2021 for Octagam 10%, its first intravenous immunoglobulin recommended for the treatment of the immune-mediated inflammatory illness known as dermatomyositis in adults.
The COVID-19 pandemic, which is currently in its last stages, is expected to boost the worldwide market for intravenous immunoglobulin. In India, for instance, Bharat Biotech is conducting a study to create monoclonal antibodies as a potential COVID-19 treatment. The Council of Scientific and Industrial Research (CSIR) has approved the project as part of its New Millennium Indian Technology Leadership strategy. Moreover, COVID-19 has caused substantial issues for patients with mental and neurological disorders due to their increased susceptibility to infection. For instance, in April 2021, Grifols, a key provider of plasma-derived medicines, contributed to a research study in collaboration with both the NIH and NIAID, to analyze an intravenous anti-SARS-CoV-2 hyperimmune globulin among outpatients. This is expected to provide a boost to the market growth in the forecast period.
Key players are adopting strategic alliances to sustain the competition. These initiatives include mergers & acquisitions, collaborations, and new product developments. For instance, in March 2022, Grifols' XEMBIFY has been approved in Europe, increasing access to novel medicines. Grifols' clearance in Europe allows it to extend its breakthrough European IG product range and offer patients and healthcare professionals another crucial therapy solution for primary and secondary immunodeficiencies. In February 2021, Pfizer gained US FDA clearance for the supplemental Biologics License Application (sBLA) with PANZYGA, an intravenous immunoglobulin to cure adult patients with severe inflammatory demyelinating polyneuropathy (CIDP).
Intravenous Immunoglobulin Market Report Highlights
Intravenous Immunoglobulin Market Growth & Trends
The global intravenous immunoglobulin market size is expected to reach USD 21.1 billion by 2030, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 7.3% from 2022 to 2030. The increasing prevalence of immunodeficiency diseases, coupled with the adoption of intravenous immunoglobulin (IVIG) therapies, is expected to fuel market growth over the forecast period. In addition, increasing off-label use of immunoglobulin and investments in the healthcare sector are factors propelling the market growth. Moreover, increasing incidences of bleeding disorders and the growing geriatric population are the factors contributing to the industry growth.
The rising incorporation of subcutaneous immunoglobulin in the treatment of primary immunodeficiency diseases as well as in replacement therapy is anticipated to provide a growth platform to the market in the next seven years. Moreover, the key market players are focusing on breakthrough product introductions to expand their global distribution network. For instance, Octapharma U.S. got FDA clearance in July 2021 for Octagam 10%, its first intravenous immunoglobulin recommended for the treatment of the immune-mediated inflammatory illness known as dermatomyositis in adults.
The COVID-19 pandemic, which is currently in its last stages, is expected to boost the worldwide market for intravenous immunoglobulin. In India, for instance, Bharat Biotech is conducting a study to create monoclonal antibodies as a potential COVID-19 treatment. The Council of Scientific and Industrial Research (CSIR) has approved the project as part of its New Millennium Indian Technology Leadership strategy. Moreover, COVID-19 has caused substantial issues for patients with mental and neurological disorders due to their increased susceptibility to infection. For instance, in April 2021, Grifols, a key provider of plasma-derived medicines, contributed to a research study in collaboration with both the NIH and NIAID, to analyze an intravenous anti-SARS-CoV-2 hyperimmune globulin among outpatients. This is expected to provide a boost to the market growth in the forecast period.
Key players are adopting strategic alliances to sustain the competition. These initiatives include mergers & acquisitions, collaborations, and new product developments. For instance, in March 2022, Grifols' XEMBIFY has been approved in Europe, increasing access to novel medicines. Grifols' clearance in Europe allows it to extend its breakthrough European IG product range and offer patients and healthcare professionals another crucial therapy solution for primary and secondary immunodeficiencies. In February 2021, Pfizer gained US FDA clearance for the supplemental Biologics License Application (sBLA) with PANZYGA, an intravenous immunoglobulin to cure adult patients with severe inflammatory demyelinating polyneuropathy (CIDP).
Intravenous Immunoglobulin Market Report Highlights
- The hypogammaglobulinemia application segment held the third-largest revenue share in 2021. This can be attributed to the increasing demand for immunoglobulin replacement therapies to treat hypogammaglobulinemia diseases, which is driven by rising awareness levels amongst patients and increasing incidences of the disease
- The hospital pharmacy distribution channel segment dominated the market with a revenue share of over 55.0% in 2021 owing to the large network of hospitals and the convenient range of products that are easily accessible through hospital pharmacies. Furthermore, hospitals offer fast reimbursement, treatment, and proper care to a large number of patients, enabling a surge in the prevalence of patients selecting hospital pharmacies
- The specialty pharmacy distribution channel segment is anticipated to expand at a lucrative CAGR of 8.9% during the forecast period as specialty pharmacies enable easy treatment at home
- North America held the largest share in terms of revenue in 2021 due to the presence of a well-regulated healthcare system, the larger pool of target population, and high patient awareness pertinent to the plasma protein products
- Asia Pacific is expected to register a significant CAGR of 8.4% over the forecast period owing to the increasing number of patients with bleeding disorders and the growing number of CIDP patients
- Countries such as India, China, and South Africa are expected to witness significant growth over the forecast period owing to improving healthcare facilities, rising healthcare expenditure, and growing public awareness regarding immune deficiency disorders
- The Kawasaki disease application segment is expected to expand at a lucrative CAGR of 9.6% from 2022 to 2030 owing to the massive adoption of IVIG treatment in the aforementioned disease management
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Country wise market calculation
1.2 Region based segment share calculation
1.3 Primary Sources
1.4 List of secondary sources
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 IVIG INDUSTRY OUTLOOK
3.1 Market segmentation
3.2 Market size and growth prospects
3.3 IVIG: Market dynamics
3.3.1 Market driver analysis
3.3.1.1 Rising prevalence of immunodeficiency diseases
3.3.1.2 Increasing adoption of immunoglobulin replacement therapy
3.3.1.3 Rising geriatric population
3.3.2 Market restraint analysis
3.3.2.1 Cost Intensive nature of immunoglobulin replacement therapy
3.3.2.2 Stringent regulations pertaining to production and approval
3.4 Industry analysis - Porter’s
3.5 Key Opportunities Prioritized
3.6 IVIG Competitive Landscape, 2021
3.6.1 Company Market Share Analysis, 2021
3.6.2 Competitive Landscape: Market Position Analysis
3.7 IVIG - PESTEL analysis
CHAPTER 4 IVIG MARKET APPLICATION OUTLOOK
4.1 IVIG revenue share by application, 2021 & 2030
4.2 Hypogammaglobulinemia
4.2.1 Hypogammaglobulinemia market, 2018 - 2030 (USD Million)
4.3 CIDP
4.3.1 CIDP market, 2018 - 2030 (USD Million)
4.4 Immunodeficiency diseases
4.4.1 Immunodeficiency diseases market, 2018 - 2030 (USD Million)
4.5 Congenital AIDS
4.5.1 Congenital AIDS market, 2018 - 2030 (USD Million)
4.6 Chronic Lymphocytic Leukemia
4.6.1 Chronic lymphocytic leukemia market, 2018 - 2030 (USD Million)
4.7 Myasthenia gravis
4.7.1 Myasthenia gravismarket, 2018 - 2030 (USD Million)
4.8 Multifocal motor neuropathy
4.8.1 Multifocal motor neuropathy market, 2018 - 2030 (USD Million)
4.9 ITP
4.9.1 ITP market, 2018 - 2030 (USD Million)
4.10 Kawasaki disease
4.10.1 Kawasaki disease market, 2018 - 2030 (USD Million)
4.11 Guillain-Barre syndrome
4.11.1 Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
4.12 Others
4.12.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 5 IMMUNOGLOBULIN OUTLOOK BY DISTRIBUTION CHANNEL
5.1 Immunoglobulin revenue share, by distribution channel, 2021 & 2030
5.2 Hospital Pharmacy
5.2.1 Hospital pharmacy market, 2018 - 2030 (USD Million)
5.3 Specialty Pharmacy
5.3.1 Specialty pharmacy market, 2018 - 2030 (USD Million)
5.4 Others
5.4.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 6 IMMUNOGLOBULIN MARKET CLINICAL TRIAL OUTLOOK
6.1 IgG
6.1.1 Clinical interpretation of IgG
6.2 IgA
6.2.1 Clinical interpretation of IgA
6.3 IgM
6.3.1 Clinical interpretation of IgM
6.4 IgE
6.4.1 Clinical interpretation of IgE
6.5 IgD
CHAPTER 7 IVIG REGIONAL OUTLOOK
7.1 IVIG market share, by region, 2021 & 2030
7.2 North America
7.2.1 North America IVIG market, 2018 - 2030 (USD Million)
7.2.2 North America Clinical Trial
7.2.3 U.S.
7.2.3.1 U.S. IVIG market, 2018 - 2030 (USD Million)
7.2.4 Canada
7.2.4.1 Canada IVIG market, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe IVIG market, 2018 - 2030 (USD Million)
7.3.2 Europe Clinical Trial
7.3.3 U.K.
7.3.3.1 U.K. IVIG market, 2018 - 2030 (USD Million)
7.3.4 Germany
7.3.4.1 Germany IVIG market, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific IVIG market, 2018 - 2030 (USD Million)
7.4.2 Asia Pacific Clinical Trial
7.4.3 Japan
7.4.3.1 Japan IVIG market, 2018 - 2030 (USD Million)
7.4.4 China
7.4.4.1 China IVIG market, 2018 - 2030 (USD Million)
7.4.5 India
7.4.5.1 India IVIG market, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America IVIG market, 2018 - 2030 (USD Million)
7.5.2 Clinical Trial
7.5.3 Brazil
7.5.3.1 Brazil IVIG market, 2018 - 2030 (USD Million)
7.5.4 Mexico
7.5.4.1 Mexico IVIG market, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 MEA IVIG market, 2018 - 2030 (USD Million)
7.6.2 MEA Clinical Trial
7.6.3 South Africa
7.6.3.1 South Africa IVIG market, 2018 - 2030 (USD Million)
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Biotest AG
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Octapharma AG
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Baxter International Inc.
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 LFB Biotechnologies
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 China Biologics Products, Inc.
8.5.1 Financial Performance
8.5.2 Product Benchmarking
8.5.3 Strategic Initiatives
8.6 Grifols SA
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Kedrion Biopharma
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 CSL Behring
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 BDI Pharma, Inc.
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
1.1 Country wise market calculation
1.2 Region based segment share calculation
1.3 Primary Sources
1.4 List of secondary sources
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 IVIG INDUSTRY OUTLOOK
3.1 Market segmentation
3.2 Market size and growth prospects
3.3 IVIG: Market dynamics
3.3.1 Market driver analysis
3.3.1.1 Rising prevalence of immunodeficiency diseases
3.3.1.2 Increasing adoption of immunoglobulin replacement therapy
3.3.1.3 Rising geriatric population
3.3.2 Market restraint analysis
3.3.2.1 Cost Intensive nature of immunoglobulin replacement therapy
3.3.2.2 Stringent regulations pertaining to production and approval
3.4 Industry analysis - Porter’s
3.5 Key Opportunities Prioritized
3.6 IVIG Competitive Landscape, 2021
3.6.1 Company Market Share Analysis, 2021
3.6.2 Competitive Landscape: Market Position Analysis
3.7 IVIG - PESTEL analysis
CHAPTER 4 IVIG MARKET APPLICATION OUTLOOK
4.1 IVIG revenue share by application, 2021 & 2030
4.2 Hypogammaglobulinemia
4.2.1 Hypogammaglobulinemia market, 2018 - 2030 (USD Million)
4.3 CIDP
4.3.1 CIDP market, 2018 - 2030 (USD Million)
4.4 Immunodeficiency diseases
4.4.1 Immunodeficiency diseases market, 2018 - 2030 (USD Million)
4.5 Congenital AIDS
4.5.1 Congenital AIDS market, 2018 - 2030 (USD Million)
4.6 Chronic Lymphocytic Leukemia
4.6.1 Chronic lymphocytic leukemia market, 2018 - 2030 (USD Million)
4.7 Myasthenia gravis
4.7.1 Myasthenia gravismarket, 2018 - 2030 (USD Million)
4.8 Multifocal motor neuropathy
4.8.1 Multifocal motor neuropathy market, 2018 - 2030 (USD Million)
4.9 ITP
4.9.1 ITP market, 2018 - 2030 (USD Million)
4.10 Kawasaki disease
4.10.1 Kawasaki disease market, 2018 - 2030 (USD Million)
4.11 Guillain-Barre syndrome
4.11.1 Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
4.12 Others
4.12.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 5 IMMUNOGLOBULIN OUTLOOK BY DISTRIBUTION CHANNEL
5.1 Immunoglobulin revenue share, by distribution channel, 2021 & 2030
5.2 Hospital Pharmacy
5.2.1 Hospital pharmacy market, 2018 - 2030 (USD Million)
5.3 Specialty Pharmacy
5.3.1 Specialty pharmacy market, 2018 - 2030 (USD Million)
5.4 Others
5.4.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 6 IMMUNOGLOBULIN MARKET CLINICAL TRIAL OUTLOOK
6.1 IgG
6.1.1 Clinical interpretation of IgG
6.2 IgA
6.2.1 Clinical interpretation of IgA
6.3 IgM
6.3.1 Clinical interpretation of IgM
6.4 IgE
6.4.1 Clinical interpretation of IgE
6.5 IgD
CHAPTER 7 IVIG REGIONAL OUTLOOK
7.1 IVIG market share, by region, 2021 & 2030
7.2 North America
7.2.1 North America IVIG market, 2018 - 2030 (USD Million)
7.2.2 North America Clinical Trial
7.2.3 U.S.
7.2.3.1 U.S. IVIG market, 2018 - 2030 (USD Million)
7.2.4 Canada
7.2.4.1 Canada IVIG market, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe IVIG market, 2018 - 2030 (USD Million)
7.3.2 Europe Clinical Trial
7.3.3 U.K.
7.3.3.1 U.K. IVIG market, 2018 - 2030 (USD Million)
7.3.4 Germany
7.3.4.1 Germany IVIG market, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific IVIG market, 2018 - 2030 (USD Million)
7.4.2 Asia Pacific Clinical Trial
7.4.3 Japan
7.4.3.1 Japan IVIG market, 2018 - 2030 (USD Million)
7.4.4 China
7.4.4.1 China IVIG market, 2018 - 2030 (USD Million)
7.4.5 India
7.4.5.1 India IVIG market, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America IVIG market, 2018 - 2030 (USD Million)
7.5.2 Clinical Trial
7.5.3 Brazil
7.5.3.1 Brazil IVIG market, 2018 - 2030 (USD Million)
7.5.4 Mexico
7.5.4.1 Mexico IVIG market, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 MEA IVIG market, 2018 - 2030 (USD Million)
7.6.2 MEA Clinical Trial
7.6.3 South Africa
7.6.3.1 South Africa IVIG market, 2018 - 2030 (USD Million)
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Biotest AG
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Octapharma AG
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Baxter International Inc.
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 LFB Biotechnologies
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 China Biologics Products, Inc.
8.5.1 Financial Performance
8.5.2 Product Benchmarking
8.5.3 Strategic Initiatives
8.6 Grifols SA
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Kedrion Biopharma
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 CSL Behring
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 BDI Pharma, Inc.
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
LIST OF TABLES
TABLE 1 IVIG - Industry Snapshot & Key Buying Criteria, 2018 - 2030
TABLE 2 Global IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 3 Global immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 4 Global IVIGmarket, by region, 2018 - 2030 (USD Million)
TABLE 5 IVIG - Key market driver analysis
TABLE 6 IVIG - Key market restraint analysis
TABLE 7 Clinical Interpretation of IgG
TABLE 8 Clinical Interpretation of IgA
TABLE 9 Clinical interpretation of IgM
TABLE 10 Clinical interpretation of IgE
TABLE 11 North America IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 12 North America immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 13 North America (U.S. and Canada) Clinical Trial
TABLE 14 U.S. IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 15 U.S. immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 16 Canada IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 17 Canada immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 18 Europe IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 19 Europe immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 20 Europe Clinical Trial
TABLE 21 U.K. IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 22 U.K. immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 23 Germany IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 24 Germany immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 25 Asia Pacific IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 26 Asia Pacific immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 27 Asia Pacific (India, Japan, China) Clinical Trial
TABLE 28 Japan IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 29 Japan immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 30 China IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 31 China immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 32 India IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 33 India immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 34 Latin America IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 35 Latin America immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 36 Latin America (Brazil) Clinical Trial
TABLE 37 Brazil IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 38 Brazil immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 39 Mexico IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 40 Mexico immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 41 MEA IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 42 MEA immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 43 MEA (South Africa) Clinical Trial
TABLE 44 South Africa IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 45 South Africa immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 1 IVIG - Industry Snapshot & Key Buying Criteria, 2018 - 2030
TABLE 2 Global IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 3 Global immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 4 Global IVIGmarket, by region, 2018 - 2030 (USD Million)
TABLE 5 IVIG - Key market driver analysis
TABLE 6 IVIG - Key market restraint analysis
TABLE 7 Clinical Interpretation of IgG
TABLE 8 Clinical Interpretation of IgA
TABLE 9 Clinical interpretation of IgM
TABLE 10 Clinical interpretation of IgE
TABLE 11 North America IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 12 North America immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 13 North America (U.S. and Canada) Clinical Trial
TABLE 14 U.S. IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 15 U.S. immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 16 Canada IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 17 Canada immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 18 Europe IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 19 Europe immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 20 Europe Clinical Trial
TABLE 21 U.K. IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 22 U.K. immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 23 Germany IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 24 Germany immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 25 Asia Pacific IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 26 Asia Pacific immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 27 Asia Pacific (India, Japan, China) Clinical Trial
TABLE 28 Japan IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 29 Japan immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 30 China IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 31 China immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 32 India IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 33 India immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 34 Latin America IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 35 Latin America immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 36 Latin America (Brazil) Clinical Trial
TABLE 37 Brazil IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 38 Brazil immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 39 Mexico IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 40 Mexico immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 41 MEA IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 42 MEA immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
TABLE 43 MEA (South Africa) Clinical Trial
TABLE 44 South Africa IVIG market, by application, 2018 - 2030 (USD Million)
TABLE 45 South Africa immunoglobulin market, by distribution channel, 2018 - 2030 (USD Million)
LIST OF FIGURES
FIG. 1 IVIG: Market segmentation
FIG. 2 Global IVIG market, 2018 - 2030 (USD Million)
FIG. 3 IVIG: Market dynamics
FIG. 4 European immunodeficiency disorders incidence rate, 2021
FIG. 5 Global percentage of population, by age group, 2000 and 2050
FIG. 6 IVIG market - Porter’s analysis
FIG. 7 By application, 2021
FIG. 8 By distribution channel, 2021
FIG. 9 Immunoglobulin company market share, 2021
FIG. 10 Competitive Landscape Analysis, 2021
FIG. 11 IVIGmarket - PESTEL analysis
FIG. 12 IVIG revenue share by application, 2021 & 2030
FIG. 13 Hypogammaglobulinemia market, 2018 - 2030 (USD Million)
FIG. 14 CIDP market, 2018 - 2030 (USD Million)
FIG. 15 Immunodeficiency diseases market, 2018 - 2030 (USD Million)
FIG. 16 Congenital AIDS market, 2018 - 2030 (USD Million)
FIG. 17 Chronic lymphocytic leukemia market, 2018 - 2030 (USD Million)
FIG. 18 Myasthenia gravis market, 2018 - 2030 (USD Million)
FIG. 19 Multifocal motor neuropathy market, 2018 - 2030 (USD Million)
FIG. 20 ITP market, 2018 - 2030 (USD Million)
FIG. 21 Kawasaki disease market, 2018 - 2030 (USD Million)
FIG. 22 Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
FIG. 23 Others market, 2018 - 2030 (USD Million)
FIG. 24 IVIG revenue share by application, 2021 & 2030
FIG. 25 Intravenous market, 2018 - 2030 (USD Million)
FIG. 26 Subcutaneous market, 2018 - 2030 (USD Million)
FIG. 27 IVIGs market share by distribution channel, 2021 & 2030
FIG. 28 Hospital pharmacy market, 2018 - 2030 (USD Million)
FIG. 29 Specialty pharmacy market, 2018 - 2030 (USD Million)
FIG. 30 Others market, 2018 - 2030 (USD Million)
FIG. 31 IVIGs market share by countries, 2021 & 2030
FIG. 32 North America IVIG market, 2018 - 2030 (USD Million)
FIG. 33 U.S. IVIG market, 2018 - 2030 (USD Million)
FIG. 34 Canada IVIG market, 2018 - 2030 (USD Million)
FIG. 35 Europe IVIG market, 2018 - 2030 (USD Million)
FIG. 36 U.K. IVIG market, 2018 - 2030 (USD Million)
FIG. 37 Germany IVIG market, 2018 - 2030 (USD Million)
FIG. 38 Asia Pacific IVIG market, 2018 - 2030 (USD Million)
FIG. 39 Japan IVIG market, 2018 - 2030 (USD Million)
FIG. 40 China IVIG market, 2018 - 2030 (USD Million)
FIG. 41 India IVIG market, 2018 - 2030 (USD Million)
FIG. 42 Latin America IVIG market, 2018 - 2030 (USD Million)
FIG. 43 Brazil IVIG market, 2018 - 2030 (USD Million)
FIG. 44 Mexico IVIG market, 2018 - 2030 (USD Million)
FIG. 45 MEA IVIG market, 2018 - 2030 (USD Million)
FIG. 46 South Africa IVIG market, 2018 - 2030 (USD Million)
FIG. 1 IVIG: Market segmentation
FIG. 2 Global IVIG market, 2018 - 2030 (USD Million)
FIG. 3 IVIG: Market dynamics
FIG. 4 European immunodeficiency disorders incidence rate, 2021
FIG. 5 Global percentage of population, by age group, 2000 and 2050
FIG. 6 IVIG market - Porter’s analysis
FIG. 7 By application, 2021
FIG. 8 By distribution channel, 2021
FIG. 9 Immunoglobulin company market share, 2021
FIG. 10 Competitive Landscape Analysis, 2021
FIG. 11 IVIGmarket - PESTEL analysis
FIG. 12 IVIG revenue share by application, 2021 & 2030
FIG. 13 Hypogammaglobulinemia market, 2018 - 2030 (USD Million)
FIG. 14 CIDP market, 2018 - 2030 (USD Million)
FIG. 15 Immunodeficiency diseases market, 2018 - 2030 (USD Million)
FIG. 16 Congenital AIDS market, 2018 - 2030 (USD Million)
FIG. 17 Chronic lymphocytic leukemia market, 2018 - 2030 (USD Million)
FIG. 18 Myasthenia gravis market, 2018 - 2030 (USD Million)
FIG. 19 Multifocal motor neuropathy market, 2018 - 2030 (USD Million)
FIG. 20 ITP market, 2018 - 2030 (USD Million)
FIG. 21 Kawasaki disease market, 2018 - 2030 (USD Million)
FIG. 22 Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
FIG. 23 Others market, 2018 - 2030 (USD Million)
FIG. 24 IVIG revenue share by application, 2021 & 2030
FIG. 25 Intravenous market, 2018 - 2030 (USD Million)
FIG. 26 Subcutaneous market, 2018 - 2030 (USD Million)
FIG. 27 IVIGs market share by distribution channel, 2021 & 2030
FIG. 28 Hospital pharmacy market, 2018 - 2030 (USD Million)
FIG. 29 Specialty pharmacy market, 2018 - 2030 (USD Million)
FIG. 30 Others market, 2018 - 2030 (USD Million)
FIG. 31 IVIGs market share by countries, 2021 & 2030
FIG. 32 North America IVIG market, 2018 - 2030 (USD Million)
FIG. 33 U.S. IVIG market, 2018 - 2030 (USD Million)
FIG. 34 Canada IVIG market, 2018 - 2030 (USD Million)
FIG. 35 Europe IVIG market, 2018 - 2030 (USD Million)
FIG. 36 U.K. IVIG market, 2018 - 2030 (USD Million)
FIG. 37 Germany IVIG market, 2018 - 2030 (USD Million)
FIG. 38 Asia Pacific IVIG market, 2018 - 2030 (USD Million)
FIG. 39 Japan IVIG market, 2018 - 2030 (USD Million)
FIG. 40 China IVIG market, 2018 - 2030 (USD Million)
FIG. 41 India IVIG market, 2018 - 2030 (USD Million)
FIG. 42 Latin America IVIG market, 2018 - 2030 (USD Million)
FIG. 43 Brazil IVIG market, 2018 - 2030 (USD Million)
FIG. 44 Mexico IVIG market, 2018 - 2030 (USD Million)
FIG. 45 MEA IVIG market, 2018 - 2030 (USD Million)
FIG. 46 South Africa IVIG market, 2018 - 2030 (USD Million)
